399 related articles for article (PubMed ID: 16236745)
1. Trastuzumab in the treatment of breast cancer.
Hortobagyi GN
N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
[No Abstract] [Full Text] [Related]
2. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
3. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
4. Trastuzumab in breast cancer.
Gounaris IG
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470950
[No Abstract] [Full Text] [Related]
5. Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.
Dent R; Clemons M
Cancer Treat Rev; 2006 Apr; 32(2):144-8. PubMed ID: 16517084
[No Abstract] [Full Text] [Related]
6. Trastuzumab in breast cancer.
Gilbert SG
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16467555
[No Abstract] [Full Text] [Related]
7. Current perspective - trastuzumab.
Hall PS; Cameron DA
Eur J Cancer; 2009 Jan; 45(1):12-8. PubMed ID: 19042123
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant trastuzumab for HER2-positive early breast cancer.
Palmieri FM; Myatt CV; Perez EA
Clin J Oncol Nurs; 2010 Jun; 14(3):326-36. PubMed ID: 20529794
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab in breast cancer.
Banna GL; Santoro A
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
[No Abstract] [Full Text] [Related]
11. [Medical, non-endocrine treatment of metastatic breast cancer--a status].
Lindberg H; Nielsen DL; Kamby C
Ugeskr Laeger; 2007 Apr; 169(17):1556-60. PubMed ID: 17484824
[TBL] [Abstract][Full Text] [Related]
12. [Very small breast cancer, HER2 positive, and trastuzumab in adjuvant treatment].
Vyzula R
Klin Onkol; 2010; 23(1):21-4. PubMed ID: 20192070
[TBL] [Abstract][Full Text] [Related]
13. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
Seidman AD
Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
15. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
[TBL] [Abstract][Full Text] [Related]
16. [Herceptin (trastuzumab)].
Yamashiro H; Toi M
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
[TBL] [Abstract][Full Text] [Related]
17. [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].
Láng I; Hitre E
Magy Onkol; 2006; 50(4):293-302. PubMed ID: 17216002
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment.
Kell MR; Power CP
BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293849
[No Abstract] [Full Text] [Related]
19. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab.
Perez EA; Palmieri FM; Brock SM
Cancer Treat Res; 2009; 151():181-96. PubMed ID: 19593513
[No Abstract] [Full Text] [Related]
[Next] [New Search]
